BioVie Says Phase 2 SUNRISE-PD Trial Of Bezisterim In Early Parkinson's Disease Met Prespecified Endpoints, Showing Statistically Significant Motor And Non-Motor Improvements vs. Placebo

Loading news article.

BioVie Says Phase 2 SUNRISE-PD Trial Of Bezisterim In Early Parkinson's Disease Met Prespecified Endpoints, Showing Statistically Significant Motor And Non-Motor Improvements vs. Placebo | WAPE

BioVie Says Phase 2 SUNRISE-PD Trial Of Bezisterim In Early Parkinson's Disease Met Prespecified Endpoints, Showing Statistically Significant Motor And Non-Motor Improvements vs. Placebo

Article summary

Related companies

Comments —